MeSH term
Frequency | Condition_Probility | Humans | 55 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Transfection | 7 | 0.0 |
Binding Sites | 3 | 0.0 |
Cell Adhesion | 5 | 0.0 |
Immunohistochemistry | 4 | 0.0 |
Integrin alpha3 | 3 | 17.0 |
Integrin alpha6 | 2 | 10.0 |
Male | 13 | 0.0 |
Microscopy, Confocal | 3 | 0.0 |
Mutation | 2 | 0.0 |
Phenotype | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 37 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 16 | 0.0 |
Vinculin/metabolism | 2 | 8.0 |
Animals | 21 | 0.0 |
Cell Line | 13 | 0.0 |
Detergents | 2 | 1.0 |
Hamsters | 3 | 0.0 |
In Vitro | 2 | 0.0 |
Macromolecular Substances | 6 | 0.0 |
*Membrane Glycoproteins | 6 | 0.0 |
Membrane Proteins/chemistry/genetics/*metabolism | 2 | 3.0 |
Mutagenesis, Site-Directed | 3 | 0.0 |
Amino Acid Sequence | 9 | 0.0 |
Antigens, CD/genetics/*metabolism | 3 | 3.0 |
Integrin alpha3beta1/*metabolism | 2 | 50.0 |
Molecular Sequence Data | 9 | 0.0 |
Antibodies, Monoclonal/immunology | 2 | 0.0 |
Antigens, CD/immunology/*metabolism | 2 | 4.0 |
Cells, Cultured | 10 | 0.0 |
Epitopes/immunology | 2 | 0.0 |
Integrin alpha3beta1 | 8 | 25.0 |
Integrin alpha6beta1 | 4 | 21.0 |
Integrins/*metabolism | 7 | 4.0 |
K562 Cells | 3 | 0.0 |
Membrane Glycoproteins/physiology | 2 | 1.0 |
Drug Combinations | 2 | 0.0 |
Fibroblasts/metabolism | 2 | 0.0 |
Mice | 11 | 0.0 |
Cloning, Molecular | 5 | 0.0 |
Female | 13 | 0.0 |
Pregnancy | 2 | 0.0 |
Protein Binding | 7 | 0.0 |
Cell Movement | 3 | 0.0 |
Flow Cytometry | 7 | 0.0 |
Immunoblotting | 2 | 0.0 |
Precipitin Tests | 6 | 0.0 |
Tumor Cells, Cultured | 9 | 0.0 |
Middle Aged | 8 | 0.0 |
Retrospective Studies | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
Survival Rate | 2 | 0.0 |
Antibodies, Monoclonal/pharmacology | 3 | 0.0 |
Dyes | 2 | 1.0 |
Fluorescent Antibody Technique | 4 | 0.0 |
Adult | 7 | 0.0 |
Platelet Glycoprotein GPIIb-IIIa Complex/drug effects/metabolism | 2 | 66.0 |
Blotting, Western | 3 | 0.0 |
Comparative Study | 6 | 0.0 |
Immunoenzyme Techniques | 3 | 0.0 |
Integrins/metabolism | 2 | 1.0 |
Rats | 2 | 0.0 |
Antigens, CD/*metabolism | 8 | 1.0 |
Base Sequence | 5 | 0.0 |
Membrane Proteins/*metabolism | 4 | 0.0 |
Antigens, CD/chemistry/*metabolism | 2 | 5.0 |
Antigens, Differentiation, T-Lymphocyte/metabolism | 2 | 1.0 |
*Membrane Proteins | 3 | 0.0 |
Protein Conformation | 2 | 0.0 |
Protein Kinase C/*metabolism | 2 | 0.0 |
Adolescent | 3 | 0.0 |
Aged | 4 | 0.0 |
Antigens, CD/*genetics | 5 | 1.0 |
Gene Expression/immunology | 2 | 2.0 |
Membrane Glycoproteins/*genetics | 2 | 0.0 |
Antigens, CD/analysis | 2 | 0.0 |
Antigens, Surface/*analysis | 2 | 1.0 |
Cell Adhesion Molecules/analysis | 2 | 1.0 |
*Cell Adhesion | 2 | 1.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Cell Adhesion Molecules/metabolism | 2 | 0.0 |
Membrane Proteins/metabolism | 2 | 0.0 |
Extracellular Space | 2 | 8.0 |
Epithelial Cells/*immunology | 2 | 10.0 |
Immunophenotyping | 3 | 0.0 |
Integrins/analysis | 2 | 4.0 |
Mice, Knockout | 2 | 0.0 |
Platelet Glycoprotein GPIIb-IIIa Complex/*metabolism | 2 | 6.0 |
*Signal Transduction | 3 | 0.0 |
Antibodies, Monoclonal | 2 | 0.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Tolonium Chloride | 2 | 20.0 |
COS Cells | 2 | 0.0 |
Cell Movement/*physiology | 2 | 0.0 |
Cercopithecus aethiops | 2 | 0.0 |
Molecular Weight | 2 | 0.0 |
Actins/metabolism | 2 | 0.0 |
Child | 3 | 0.0 |
Child, Preschool | 3 | 0.0 |
Infant | 2 | 0.0 |
Integrin alpha4beta1 | 2 | 2.0 |
Mice, Inbred BALB C | 3 | 0.0 |
Gene Expression | 2 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Aspirin/*therapeutic use | 2 | 12.0 |
Platelet Activation/drug effects | 2 | 3.0 |
Platelet Aggregation Inhibitors/*therapeutic use | 2 | 8.0 |
Prognosis | 2 | 0.0 |
Aspirin/*pharmacology | 2 | 4.0 |
Platelet Aggregation/drug effects | 2 | 0.0 |
